skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Characterizing the Tumor Response to Treatment With Combretastatin A4 Phosphate

Abstract

Purpose: To examine the pathophysiologic impact of treatment with combretastatin A4 phosphate (CA4P) in regions of tumors that ultimately either necrose or survive treatment with this agent. Methods and Materials: Proliferation, perfusion, vessel density, and expression of vascular endothelial growth factor (VEGF) were analyzed in the KHT tumor model after treatment with CA4P. Analyses were conducted in the whole tumor and the tumor periphery. Results: Perfusion in the tumor periphery decreased 4 h after treatment, but returned to baseline 20 h later. Whole-tumor perfusion also decreased 4 h after treatment, but did not return to baseline. Vessel density decreased in the tumor as a whole, but not in the tumor periphery. No significant effect on the expression of VEGF was observed, but a decrease in proliferation in the whole tumor and the periphery was noted. Conclusions: The present study shows that those areas of a tumor that survive treatment with CA4P are affected by CA4P exposure, though only transiently. The decrease in perfusion could negatively affect therapies utilizing the combination of CA4P and conventional anticancer agents by decreasing drug delivery and tissue oxygenation. These findings suggest that the timing of CA4P treatments when used in conjunction with conventional anticancer therapiesmore » should be considered carefully.« less

Authors:
 [1];  [2]
  1. Department of Pharmacology and Therapeutics, Shands Cancer Center, University of Florida, Gainesville, FL (United States)
  2. Department of Pharmacology and Therapeutics, Shands Cancer Center, University of Florida, Gainesville, FL (United States) and Department of Radiation Oncology, Shands Cancer Center, University of Florida, Gainesville, FL (United States). E-mail: siemadw@ufl.edu
Publication Date:
OSTI Identifier:
20951635
Resource Type:
Journal Article
Resource Relation:
Journal Name: International Journal of Radiation Oncology, Biology and Physics; Journal Volume: 68; Journal Issue: 1; Other Information: DOI: 10.1016/j.ijrobp.2006.12.051; PII: S0360-3016(07)00091-0; Copyright (c) 2007 Elsevier Science B.V., Amsterdam, Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA)
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; BIOMEDICAL RADIOGRAPHY; DRUGS; GROWTH FACTORS; PHOSPHATES; SARCOMAS; THERAPY

Citation Formats

Salmon, Beth A., and Siemann, Dietmar W.. Characterizing the Tumor Response to Treatment With Combretastatin A4 Phosphate. United States: N. p., 2007. Web. doi:10.1016/j.ijrobp.2006.12.051.
Salmon, Beth A., & Siemann, Dietmar W.. Characterizing the Tumor Response to Treatment With Combretastatin A4 Phosphate. United States. doi:10.1016/j.ijrobp.2006.12.051.
Salmon, Beth A., and Siemann, Dietmar W.. Tue . "Characterizing the Tumor Response to Treatment With Combretastatin A4 Phosphate". United States. doi:10.1016/j.ijrobp.2006.12.051.
@article{osti_20951635,
title = {Characterizing the Tumor Response to Treatment With Combretastatin A4 Phosphate},
author = {Salmon, Beth A. and Siemann, Dietmar W.},
abstractNote = {Purpose: To examine the pathophysiologic impact of treatment with combretastatin A4 phosphate (CA4P) in regions of tumors that ultimately either necrose or survive treatment with this agent. Methods and Materials: Proliferation, perfusion, vessel density, and expression of vascular endothelial growth factor (VEGF) were analyzed in the KHT tumor model after treatment with CA4P. Analyses were conducted in the whole tumor and the tumor periphery. Results: Perfusion in the tumor periphery decreased 4 h after treatment, but returned to baseline 20 h later. Whole-tumor perfusion also decreased 4 h after treatment, but did not return to baseline. Vessel density decreased in the tumor as a whole, but not in the tumor periphery. No significant effect on the expression of VEGF was observed, but a decrease in proliferation in the whole tumor and the periphery was noted. Conclusions: The present study shows that those areas of a tumor that survive treatment with CA4P are affected by CA4P exposure, though only transiently. The decrease in perfusion could negatively affect therapies utilizing the combination of CA4P and conventional anticancer agents by decreasing drug delivery and tissue oxygenation. These findings suggest that the timing of CA4P treatments when used in conjunction with conventional anticancer therapies should be considered carefully.},
doi = {10.1016/j.ijrobp.2006.12.051},
journal = {International Journal of Radiation Oncology, Biology and Physics},
number = 1,
volume = 68,
place = {United States},
year = {Tue May 01 00:00:00 EDT 2007},
month = {Tue May 01 00:00:00 EDT 2007}
}